New drug combo for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (ZG005) combined with another drug (gecacitinib) and chemotherapy to see if it can help people with advanced solid tumors, especially cancer of the stomach or esophagus. The goal is to find a new treatment option that might be more effective than current approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must be able to understand the study and sign a consent form agreeing to participate.
- Your cancer must be a solid tumor that is locally advanced (has grown nearby), recurrent (has come back), or metastatic (has spread).
- You must have a life expectancy of at least 3 months.
- Your doctor must consider you suitable for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
This trial tests a combination of two new drugs, ZG005 and Gecacitinib, for people with advanced cervical cancer that has spread or come back. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.